Stockscreener 앱 받기
12.32
0.65%
0.08
Viatris Inc 주식(VTRS)의 최신 뉴스
Viatris Inc. stock rises Wednesday, outperforms market - MSN
Prescription for Growth: Why Zoetis and Viatris are Defining Healthcare’s New Winners in 2025 - FinancialContent
How Is The Market Feeling About Viatris Inc? - Benzinga
Is Viatris stock outperforming the Dow? - MSN
Viatris: Looks Cheap, But Faces Continued Contraction (NASDAQ:VTRS) - Seeking Alpha
Wall Street Recap: How strong is Viatris Inc. stock revenue growthStock Surge & Safe Capital Growth Trade Ideas - moha.gov.vn
Why Viatris Inc. stock remains on buy listsWeekly Gains Summary & Safe Entry Momentum Stock Tips - Bölüm Sonu Canavarı
Earnings Risk: How Viatris Inc. (VIA) stock trades after earningsPortfolio Gains Summary & AI Powered Buy and Sell Recommendations - ulpravda.ru
Is Viatris’ Shift Into Complex Therapies Altering The Investment Case For VTRS? - Yahoo Finance
Viatris (VTRS): Reassessing Valuation After Recent Share Price Gains and Evolving Investor Sentiment - Yahoo Finance
Opus Genetics Partner Files Supplemental NDA for Presbyopia Drug - TipRanks
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates - Yahoo News Malaysia
Is Viatris Inc. stock safe for conservative investorsEarnings Miss & Fast Moving Stock Watchlists - DonanımHaber
Viatris’ MR-146 gains IND clearance for neurotrophic keratopathy - BioWorld MedTech
Viatris secures four regulatory milestones across global pipeline By Investing.com - Investing.com Australia
Will Viatris Inc. stock outperform Nasdaq index2025 Valuation Update & Verified Technical Trade Signals - DonanımHaber
Viatris Provides Pipeline Update on Four Regulatory Milestones - The Malaysian Reserve
Update Recap: How Viatris Inc. stock valuations compare to rivalsWeekly Market Report & Fast Entry Momentum Alerts - Улправда
Chemotherapy Induced Anemia Market Intelligence Report 2025-2032, Featuring Amgen, Johnson & Johnson - PharmiWeb.com
Viatris racks up regulatory wins across therapy areas - The Pharma Letter
Viatris Says FDA Approves Octreotide Acetate, Clears MR-146 for Clinical Trials - marketscreener.com
Rally Mode: How Viatris Inc VIA stock behaves in tightening cyclesQuarterly Portfolio Summary & Scalable Portfolio Growth Methods - moha.gov.vn
Viatris secures four regulatory milestones across global pipeline - Investing.com
Viatris provides pipeline update on four regulatory milestones - marketscreener.com
Viatris Provides Pipeline Update On Four Regulatory Milestones - TradingView — Track All Markets
New gene therapy and weekly birth control patch move forward at Viatris - Stock Titan
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Malaysian Reserve
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Con - GuruFocus
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Does Viatris’ Reshaping Strategy Make Sense After Recent Share Price Swings? - Yahoo Finance
Viatris Recognized as 2025 Best Workplaces™ in Ontario and for Giving Back - The Globe and Mail
Insomnia Drugs Market Outlook 2026-2034: Trends, Shares, and Growth Analysis Featuring Merck & Co., - PharmiWeb.com
Is Viatris Stock Outperforming the Dow? - Yahoo Finance
Lost Money on Viatris Inc. (VTRS)? Contact Levi & Korsinsky to Join Class Action Before June 3, 2025 - 28/22 News
Levi & Korsinsky Notifies Shareholders of Viatris Inc.(VTRS) of a Class Action Lawsuit and an Upcoming Deadline - 28/22 News
Non-operating income (total) of Viatris, Inc. – SIX:VTRS.USD - TradingView — Track All Markets
Risk Analysis: How Viatris Inc VIA stock behaves in tightening cyclesJuly 2025 Snapshot & Verified Swing Trading Watchlist - moha.gov.vn
Discipline and Rules-Based Execution in VTRS Response - news.stocktradersdaily.com
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
How Viatris Inc stock reacts to global recession fearsJuly 2025 Spike Watch & Consistent Return Investment Signals - moha.gov.vn
Viatris to Sell Entire Equity Stake in Biocon Biologics for $815 Million - Voice Of HealthCare
Barclays Initiates Coverage of Viatris (VTRS) with Overweight Recommendation - Nasdaq
Barclays Initiates Viatris at Overweight With $15 Price Target - marketscreener.com
Viatris to sell equity stake in Biocon Biologics to Biocon for $815M - MSN
Generic Drugs Market to Reach US$ 942.69 Billion by 2033 at 7.1% - openPR.com
CAM, Khaitan act on Biocon Limited acquiring stake in Biocon Biologics from Serum, Viatris - Bar and Bench
Viatris signs agreements with Biocon on $815m stake sale - MSN
Viatris Inc. Stock Rises Friday, Outperforms Market - 富途牛牛
Viatris Sells Biocon Biologics Stake for $815 Million - TipRanks
Viatris Inc Announces Agreement to Monetize Biocon Biologics Stake - TradingView — Track All Markets
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal - MSN
Viatris to Sell its Equity Stake in Biocon Biologics for $815 Million - marketscreener.com
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal (VTRS:NASDAQ) - Seeking Alpha
1.14%
0.50%
자본화:
|
볼륨(24시간):